Systemic cancer therapy: evolution over the last 60 years.
about
Molecular Determinants of the Response of Tumor Cells to Boswellic AcidsNanoparticles for Improving Cancer Diagnosis.A novel peptide (GX1) homing to gastric cancer vasculature inhibits angiogenesis and cooperates with TNF alpha in anti-tumor therapyHigh DNA methylation pattern intratumoral diversity implies weak selection in many human colorectal cancers.Production of IL-1β by bone marrow-derived macrophages in response to chemotherapeutic drugs: synergistic effects of doxorubicin and vincristine.Advances in haematological pharmacotherapy in 21st century.In vivo imaging enables high resolution preclinical trials on patients' leukemia cells growing in mice.Cellular Senescence Promotes Adverse Effects of Chemotherapy and Cancer Relapse.The Fanconi anemia pathway and ICL repair: implications for cancer therapy.Computational approaches for translational clinical research in disease progression.Comparisons of the efficacy of a Jak1/2 inhibitor (AZD1480) with a VEGF signaling inhibitor (cediranib) and sham treatments in mouse tumors using DCE-MRI, DW-MRI, and histology.Simultaneous suppression of the MAP kinase and NF-κB pathways provides a robust therapeutic potential for thyroid cancerGenotoxic stress accelerates age-associated degenerative changes in intervertebral discsEnhanced anti-tumour effects of Vinca alkaloids given separately from cytostatic therapies.Inauhzin sensitizes p53-dependent cytotoxicity and tumor suppression of chemotherapeutic agents.Lipid rafts and clusters of apoptotic signaling molecule-enriched rafts in cancer therapy.Changing pathology with changing drugs: tumors of the gastrointestinal tract.Oncogenic properties of sphingosine kinases in haematological malignancies.Use of Systemic Therapy Concurrent With Cranial Radiotherapy for Cerebral Metastases of Solid Tumors.A front-line window of opportunity phase 2 study of sorafenib in patients with advanced nonsmall cell lung cancer: North Central Cancer Treatment Group Study N0326.Microwave assisted reactions of some azaheterocylic compounds.
P2860
Q28658165-2D2BEEDA-A407-4CB4-A912-147A2A077EB4Q30442412-274F6961-D162-4A9B-A0A7-0EBA5A09681AQ33501372-85B3C9D4-3888-4635-A79D-D3A3A9CD3C18Q33955234-2506463D-6061-48B5-AE3E-EA0250E15EDCQ34036124-8B0B1F80-443F-4BBB-8F6A-1844104D3A44Q34406838-F672291D-1DC7-482C-B576-368E21ED7631Q34541243-E46309F8-E666-4919-9450-B02DED52EE29Q34547450-396CDCAF-F4CB-42A3-80F5-7CC34B77AC97Q35024542-62B9BDAC-A740-4390-93DD-7F5CF50FE67BQ35388120-5543C3D0-DA77-4A65-86F2-3575A57C0A58Q35763899-63BF72BF-4C6A-4728-B049-B4F7DDA26307Q36012586-DE620034-1E64-4881-BDBD-5E642A60564EQ36572449-E9BECF9F-A282-4E78-B3F4-99DB337E31EEQ36709220-76D81834-9650-46F9-9902-9F9D5709BDC9Q36801098-9D5687C9-39BA-4F8C-A3EB-0392E14D16A8Q37750797-C37528ED-8637-4A90-A6B0-0F83375D54E0Q37890208-01420CBE-AC86-4180-8BC4-C6CE4797A9DDQ38092176-7585CDD3-4A4D-45F6-8F1F-FA6EACEC7D62Q38975455-1636AAA8-8D21-47D1-9E90-46EB139EB22EQ42759889-45E14CD3-F88B-45B1-A9D3-78C743399AA8Q46162294-FB16A386-C7E4-4613-8EDB-3EAF5311BD34
P2860
Systemic cancer therapy: evolution over the last 60 years.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on October 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Systemic cancer therapy: evolution over the last 60 years.
@en
Systemic cancer therapy: evolution over the last 60 years.
@nl
type
label
Systemic cancer therapy: evolution over the last 60 years.
@en
Systemic cancer therapy: evolution over the last 60 years.
@nl
prefLabel
Systemic cancer therapy: evolution over the last 60 years.
@en
Systemic cancer therapy: evolution over the last 60 years.
@nl
P2860
P356
P1433
P1476
Systemic cancer therapy: evolution over the last 60 years.
@en
P2093
Alex A Adjei
Grace K Dy
P2860
P304
P356
10.1002/CNCR.23651
P407
P433
P577
2008-10-01T00:00:00Z